Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib

被引：0

作者：

Zong, Yi ^{[2
]}

Tao, Zhigang ^{[3
]}

Jiang, Siyi ^{[4
]}

Wang, Minyuan ^{[2
]}

Yu, Weihua ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 4, Dept Gastroenterol, Yiwu, Zhejiang, Peoples R China

[2] Zhejiang Univ, Affiliated Hosp 4, Sch Med, Dept Radiol, Yiwu, Zhejiang, Peoples R China

[3] Hangzhou Canc Hosp, Dept Radiol, Hangzhou, Zhejiang, Peoples R China

[4] Zhejiang Univ, Affiliated Hosp 4, Sch Med, Intens Care Unit, Yiwu, Zhejiang, Peoples R China

来源：

DISCOVER ONCOLOGY | 2024年 / 15卷 / 01期

关键词：

Lenvatinib; Lysine specific demethylase 1; Liver cancer; Epigenetic dysregulation; PI3K; PHASE-II; HEPATOCELLULAR-CARCINOMA; SORAFENIB; RECURRENT; THERAPY;

D O I：

10.1007/s12672-024-00947-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim Lenvatinib, a multikinase inhibitor, has become a second-line treatment option for unresectable liver cancer, while its monotherapy response rate is limited. Hence, we aim to investigate whether one of the epigenetic inhibitors will be synthetic lethal with Lenvatinib in liver cancer cells.Materials and Methods We performed high-throughput drug screening in combination with Lenvatinib. And we employed CCK-8-based Bliss Synergy Score analysis, colony formation and western blotting to confirm our screening results in both HepG2 and HCCC9810 cells.Results We identified that LSD1 inhibitor Pulrodemstat in combination with Lenvatinib dramatically suppressed the PI3K-AKT signaling and induced a more significant activation of Caspase3 compared to Lenvatinib monotherapy.Conclusion Pulrodemstat synergized with Lenvatinib based on suppression of PI3K-AKT signaling and activation of apoptotic signaling.

引用

页数：8

共 50 条

[21] LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer [J].

Li, Muqing ;

Liu, Mingyu ;

Han, Wanting ;

Wang, Zifeng ;

Han, Dong ;

Patalano, Susan ;

Macoska, Jill A. ;

Balk, Steven P. ;

He, Housheng Hansen ;

Corey, Eva ;

Gao, Shuai ;

Cai, Changmeng .

CANCER RESEARCH, 2023, 83 (10) :1684-1698

[22] Glucose Transporter 1 Inhibitors Induce Autophagy and Synergize With Lenvatinib in Thyroid Cancer Cells [J].

Kuo, Chi-Yu ;

Hsu, Yi-Chiung ;

Chen, Ming-Jen ;

Lin, Chi-Hsin ;

Li, Ying-Syuan ;

Cheng, Shih-Ping .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025, 47 (02) :615-624

[23] High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients [J].

Derr, Remco S. ;

van Hoesel, Anneke Q. ;

Benard, Anne ;

Goossens-Beumer, Ines J. ;

Sajet, Anita ;

Dekker-Ensink, N. Geeske ;

de Kruijf, Esther M. ;

Bastiaannet, Esther ;

Smit, Vincent T. H. B. M. ;

van de Velde, Cornelis J. H. ;

Kuppen, Peter J. K. .

BMC CANCER, 2014, 14

[24] Clinical features of aflatoxin B1-exposed patients with liver cancer and the molecular mechanism of aflatoxin B1 on liver cancer cells [J].

Zhou, Rui ;

Liu, Meizhen ;

Liang, Xiaoliu ;

Su, Min ;

Li, Rong .

ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2019, 71

[25] Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model [J].

Xue-Feng Liu ;

Xiao-Dong Zhu ;

Long-Hai Feng ;

Xiao-Long Li ;

Bin Xu ;

Kang-Shuai Li ;

Nan Xiao ;

Ming Lei ;

Hui-Chuan Sun ;

Zhao-You Tang .

Experimental Hematology & Oncology, 11

[26] Induction of UBQLN1-mediated PGC1α stability by isoliensinine overcame hypoxia-induced resistance in liver cancer cells [J].

Xu, Xuefen ;

Li, Wei ;

Zhou, Ya ;

Wang, Meihui ;

Ji, Shufan ;

Xia, Siwei ;

Li, Yang ;

Guo, Xiaohan ;

Huan, Sheng ;

Wang, Feixia ;

Zhang, Feng ;

Cheng, Haibo ;

Yin, Guoping ;

Zheng, Shizhong .

BIOFACTORS, 2025, 51 (02)

[27] Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study [J].

Li, Qi-mei ;

Sun, Qing-can ;

Jian, Yan ;

He, Jing-zhe ;

Zhu, Hong-bo ;

Hong, Chang ;

Zeng, Lin ;

Li, Rui-ning ;

Wang, Jia-ren ;

Li, Yan ;

Chen, Li-ya ;

Weng, Xie ;

Liu, Li ;

Dong, Han-zhi ;

Xiao, Lu-shan ;

Cui, Hao .

DISCOVER ONCOLOGY, 2023, 14 (01)

[28] Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells [J].

Katz, Tiffany A. ;

Vasilatos, Shauna N. ;

Harrington, Emily ;

Oesterreich, Steffi ;

Davidson, Nancy E. ;

Huang, Yi .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (01) :99-108

[29] Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells [J].

Zheng, Peisen ;

Xia, Yiqun ;

Shen, Xin ;

Lu, Hui ;

Chen, Yinghua ;

Xu, Chenxin ;

Qiu, Chenyu ;

Zhang, Yafei ;

Zou, Peng ;

Cui, Ri ;

Huang, Xiaoying .

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2024, 20 (01) :249-264

[30] Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells [J].

Jiang, Jiuliang ;

Yang, Pingping ;

Xu, Xinyu ;

Yuan, Huixiong ;

Zhu, Haitao .

ANTI-CANCER DRUGS, 2024, 35 (09) :789-805

← 1 2 3 4 5 →